Dabrafenib is an orally bioavailable, potent, and selective inhibitor of human wild‐type
BRAF and CRAF kinases as well as mutant forms of BRAF kinase. The aim of this phase 1 …

Purpose: Dabrafenib is a selective, potent ATP-competitive inhibitor of the BRAF V600-
mutant kinase that has demonstrated efficacy in clinical trials. We report the rationale for …

Dabrafenib is a BRAF kinase inhibitor indicated for the treatment of BRAF V600E mutation‐
positive melanoma. The population pharmacokinetics of dabrafenib, including changes over …

Dabrafenib is a small‐molecule inhibitor of BRAF kinase activity that is currently being
developed for the treatment of BRAF V600 mutation‐positive melanoma. This clinical, open …

Dabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as
monotherapy or in combination with trametinib (mitogen-activated protein kinase (MAPK) …

BRAF is one of the most commonly mutated proto-oncogenes and plays a significant role in
the development of numerous cancers of high clinical impact. Due to the commonality of …

Dabrafenib (Tafinlar®), a mutant-BRAF kinase inhibitor, emerged from GlaxoSmithKline's
research programme for the discovery of selective inhibitors of mutant BRAF kinase activity …

Activating BRAF mutations, leading to constitutive activation of the MAPK signaling pathway,
are common in a variety of human cancers. Several small molecule BRAF inhibitors have …

RAF inhibitors have transformed treatment for BRAF V600-mutant cancer patients, but
clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that …

Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We
aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in …